The future leaves
signals in time.

STAT reports that questions about the durability of UniQure's experimental Huntington's disease gene therapy matter to Wall Street, but matter less to those directly affected by the disease; one patient is not fazed by its waning effect. The therapy remains experimental, and the report draws no efficacy conclusion.

Small biotech company Invivyd is developing an injectable, low-dose monoclonal antibody intended to protect against Covid. According to the report, its pursuit of a Covid vaccine alternative has received a lift, but an FDA hurdle may await; no efficacy conclusions are stated in the item.

The Alzheimer's risk gene APOE4 may actively damage brain blood vessels and sabotage the cellular systems that remove harmful proteins. Researchers were able to reverse some of these effects in experiments, revealing promising new targets for Alzheimer's, Parkinson's and other neurodegenerative diseases; the work remains at the experimental stage.

This item is the headline of a randomized placebo-controlled trial, published by Nature Medicine, examining the effects of semaglutide on kidney disease in type 2 diabetes. No results or additional context are provided in the feed, so no outcome can be stated.

The International Neoadjuvant Melanoma Consortium (INMC) released an updated pooled analysis on five-year survival with neoadjuvant therapy in melanoma. The available context provides no further details.

STAT reports that the U.S. Department of Health and Human Services (HHS) announced new efforts to use AI to speed up and expand clinical trials. Federal health officials said the goal is to accelerate clinical research to compete with countries such as China.

Nature Medicine published this update. Read the original source for full details, conditions and limitations.

According to a Nature-sourced item, research covers watermarking AI-generated proteins in a way that preserves their function. Further details were not provided beyond the headline.

At a MAHA Institute event, Kennedy and others argued that health data should be made more accessible to researchers so they can study vaccines, chronic diseases, and autism. The report presents their arguments only and does not mention any specific measures or outcomes.

Nature Medicine published an item on a synthetic lethal drug for microsatellite instability cancers. The supplied feed context contains no further details, so the study's stage, findings, and other specifics are not stated in this item.

Nature Medicine published a randomized, double-blind, placebo-controlled trial of safiglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. The available context does not include the trial's results or findings.

ScienceDaily published this update. Read the original source for full details, conditions and limitations.

ScienceDaily published this update. Read the original source for full details, conditions and limitations.

Nature Biotechnology published this update. Read the original source for full details, conditions and limitations.

Nature Biotechnology published this update. Read the original source for full details, conditions and limitations.

Nature Medicine published this update. Read the original source for full details, conditions and limitations.

The article explores emerging genome editing tools that could exceed CRISPR's capabilities, offering a guide to these new editors.